By day 21, mice treated with ABI-171 exhibited significant reductions in BLM-induced lung collagen and fibronectin levels (Figure 2F,G), underscoring the importance of targeting fibronectin in IPF management. The gene discussed is FN1; the disease is idiopathic pulmonary fibrosis.